Loading…
United Therapeutics Corporation is projected to rise to $578.86 by 2027, a +11% move from its current price of $523.63. UTHR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $518.39 | $523.82 | $529.31 | +0.04% |
| Aug 1 | $516.34 | $524.01 | $531.79 | +0.07% |
| Aug 2 | $514.82 | $524.19 | $533.74 | +0.11% |
| Aug 3 | $513.56 | $524.38 | $535.43 | +0.14% |
| Aug 4 | $512.49 | $524.57 | $536.94 | +0.18% |
| Aug 5 | $511.53 | $524.76 | $538.33 | +0.22% |
| Aug 6 | $510.67 | $524.95 | $539.62 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $510.67 | $524.95 | $539.62 | +0.25% |
| Week 2 | $506.14 | $526.26 | $547.19 | +0.50% |
| Week 3 | $502.98 | $527.59 | $553.40 | +0.76% |
| Week 4 | $500.53 | $528.91 | $558.90 | +1.01% |
| Week 5 | $498.53 | $530.24 | $563.96 | +1.26% |
| Week 6 | $496.85 | $531.57 | $568.72 | +1.52% |
| Week 7 | $495.41 | $532.91 | $573.24 | +1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Its portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin (treprostinil) injection, Orenitram (treprostinil) tablets, Adcirca, Unituxin (dinutuximab) injection, and Remunity Pump, among other programs. It is also involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH and related areas.
The company was founded in 1996 and is headquartered in Silver Spring, Maryland. It engages in licensing and collaboration agreements with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. to advance its development efforts.
United Therapeutics Corporation (UTHR) is a Healthcare company with a current price of $527.07 and a market cap of $26.25B. It holds a rank of 477 among listed assets.
The stock’s price outlook is reflected in a year-by-year forecast that shows a progression from a 2026 average price of $527.07 toward substantially higher long-term values, with bullish sentiment evident from 2029 onward.
The forecast highlights a rising trajectory: 2030 average $822.68, 2040 average $1,919.02, and 2050 average $3,963.38, with corresponding returns (ROI) of 56.1%, 264.1%, and 652% respectively, indicating a strong long-term bullish outlook.
A major floor 5.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 7.7% above — a clean break opens room to run.
A major ceiling 14.0% above — clearing it would confirm fresh momentum.
Key UTHR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UTHR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $527.33 | Sell | $527.47 | Sell |
| MA 10 | $529.83 | Sell | $530.55 | Sell |
| MA 20 | $538.51 | Sell | $535.59 | Sell |
| MA 50 | $547.07 | Sell | $543.36 | Sell |
| MA 100 | $552.75 | Sell | $537.74 | Sell |
| MA 200 | $513.18 | Buy | $505.30 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.47 | Neutral |
| Stoch RSI (14) | 14.60 | Buy |
| CCI (20) | -97.65 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.89 | Sell |
| ROC (12) | -4.28 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -14.09 | Sell |
| Ultimate (7,14,28) | 31.36 | Neutral |
| Momentum (10) | -3.03 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 525.91 | Sell |
| ADX (14) | 13.92 | Neutral |
| ATR (14) | 5.37 | Info |
The 30-day range is $488.33 to $568.88, showing notable activity within that band.
RSI(14) is 40, indicating neutral momentum, while the 50-day simple moving average is $551.01 and the 200-day simple moving average is $511.69.
Near-term support is listed at $526.66 and resistance at $563.70, placing the current price of $527.07 close to support with upside potential if resistance is breached.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $464.93 | $523.63 | $661.40 | 0% | Neutral | |
| $474.57 | $578.86 | $737.86 | +11% | Neutral | |
| $499.09 | $620.34 | $812.42 | +18% | Neutral | |
| $573.29 | $723.64 | $968.07 | +38% | Bullish | |
| $635.88 | $813.56 | $1,108.10 | +55% | Bullish | |
| $729.75 | $945.10 | $1,307.73 | +80% | Bullish | |
| $819.17 | $1,072.95 | $1,505.85 | +105% | Bullish | |
| $800.91 | $1,060.11 | $1,507.17 | +102% | Bullish | |
| $840.83 | $1,124.04 | $1,617.23 | +115% | Bullish | |
| $917.48 | $1,238.14 | $1,801.29 | +136% | Bullish | |
| $1,336.71 | $1,881.60 | $2,869.01 | +259% | Bullish | |
| $2,592.11 | $3,913.49 | $6,397.09 | +647% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $464.93 | $523.63 | $613.22 | +0.00% |
| August 2026 | $463.62 | $540.84 | $643.16 | +3.29% |
| September 2026 | $461.20 | $541.03 | $649.30 | +0.04% |
| October 2026 | $450.06 | $530.35 | $641.14 | -1.97% |
| November 2026 | $451.35 | $533.86 | $649.23 | +0.66% |
| December 2026 | $455.77 | $540.93 | $661.40 | +1.32% |
Click any year to see its month-by-month UTHR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect UTHR to range from $464.93 to $661.40 through 2026. The $523.63 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The UTHR price prediction for 2027 points to an average of $578.86 (low $474.57, high $737.86) — a potential gain of +11% on today's $523.63. A consolidation phase looks the most probable path here.
In 2028, UTHR is projected to trade between $499.09 and $812.42, averaging $620.34 — a potential gain of +18% from today's $523.63. That is up +7% on the projected 2027 average. Price action looks broadly range-bound.
United Therapeutics Corporation's 2029 outlook centres on $723.64, within a $573.29 to $968.07 range. That is up +17% on the projected 2028 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, UTHR could reach as high as $1,108.10, with a base case around $813.56 and support toward $635.88 — roughly +55% from $523.63. Momentum favours further upside here.
Expect UTHR to range from $729.75 to $1,307.73 through 2031. The $945.10 average target implies a +80% move from current prices. That is up +16% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The UTHR price prediction for 2032 points to an average of $1,072.95 (low $819.17, high $1,505.85) — a potential gain of +105% on today's $523.63. Momentum favours further upside here.
In 2033, UTHR is projected to trade between $800.91 and $1,507.17, averaging $1,060.11 — a potential gain of +102% from today's $523.63. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
United Therapeutics Corporation's 2034 outlook centres on $1,124.04, within a $840.83 to $1,617.23 range. That is up +6% on the projected 2033 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2035, UTHR could reach as high as $1,801.29, with a base case around $1,238.14 and support toward $917.48 — roughly +136% from $523.63. Buyers look set to stay in control over this stretch.
Expect UTHR to range from $1,336.71 to $2,869.01 through 2040. The $1,881.60 average target implies a +259% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The UTHR price prediction for 2050 points to an average of $3,913.49 (low $2,592.11, high $6,397.09) — a potential gain of +647% on today's $523.63. Buyers look set to stay in control over this stretch.
Investing $1,000 in UTHR today (≈ 1.909745 UTHR) could be worth
$7,473.78
+$6,473.78 (+647%) by 2050 · US Dollar
Based on the average projected UTHR price of $3,913.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UTHRwould be worth at today's price.
$1,000 invested in UTHR on Jul 28, 2025 (≈ 3.354129 UTHR) would be worth
$1,756.32
+$756.32 (+75.6%) today · 1.76× · US Dollar
Based on a UTHR entry price of $298.14 vs. today's $523.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $535.83 | $977.23 | -2.3% |
| 1 month ago | $544.92 | $960.93 | -3.9% |
| 3 months ago | $571.07 | $916.93 | -8.3% |
| 6 months ago | $467.7 | $1,119.59 | +12.0% |
| 1 year ago | $298.14 | $1,756.32 | +75.6% |
| All time (5.0y) ago | $179.86 | $2,911.32 | +191.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UTHR forecast.
Our base-case forecast reaches $1,000.00 around 2032.
Implied market cap at $1,000.00: $49.8B
The multi-year forecast points to a bullish trend with higher averages and ROIs into the 2030s and beyond. The 2030 forecast shows an average price of $822.68 with a 56.1% ROI, and a bullish sentiment for that year.
Looking further ahead, the 2040 forecast lists an average price of $1,919.02 and a 264.1% ROI, still categorized as bullish. By 2050, the forecast envisions an average price of $3,963.38 with a 652% ROI, continuing the bullish outlook.
These figures illustrate a steadily rising long-term trajectory, but they are estimates and not guarantees; ongoing market conditions and other factors could influence actual outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $822.68, with a min of $642.88 and a max of $1,120.84, and a 56.1% ROI, with a bullish sentiment.
Forecasts indicate a bullish sentiment from 2029 onward, with the average price rising to $822.68 by 2030 and continuing to grow to $3,963.38 by 2050, yielding strong ROIs such as 56.1% (2030), 264.1% (2040), and 652% (2050). These are estimates, not guarantees.
Yes. The 2030 maximum price in the forecast is $1,120.84, with the 2029 maximum at $976.98, indicating a potential exceedance of $1,000 within the forecast window.
The 2050 forecast shows an average price of $3,963.38, a maximum of $6,479.27, and a minimum of $2,624.88, with a 652% ROI and bullish sentiment.
United Therapeutics Corporation Community Discussion
0Share your United Therapeutics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.